TORRENT PHARMACEUTICALS L Latest Share Price (TORNTPHARM)
TODAY IN ONE LINE
TORNTPHARM is little changed at ₹4593.50 on light volume — a quiet consolidation day.
With a market cap of ₹1.74 L Cr., it trades at a P/E of 71.32. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
TORRENT PHARMACEUTICALS L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 23.3%
- ●High Promoter HoldingPromoters hold 60.8% skin-in-the-game
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 21.7% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 72.7x
Latest TORRENT PHARMACEUTICALS L News
What changed recently?
Recent events, corporate actions, and announcements.
TORRENT PHARMACEUTICALS L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for TORRENT PHARMACEUTICALS L, framed against the sector median so the premium or discount is obvious at a glance.
TORRENT PHARMACEUTICALS L trades at a P/E of 71.32× and P/B of 18.54×, against the Healthcare sector median P/E of 39.94×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
TORRENT PHARMACEUTICALS L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for TORRENT PHARMACEUTICALS L — derived from the latest tape, not yesterday's close.
TORRENT PHARMACEUTICALS L last traded at ₹4,593.5 with an intraday range of ₹4,550.4–₹4,618.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹4593.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 4761.80 | +168.30 | +3.66% |
| R3 | 4693.30 | +99.80 | +2.17% |
| R2 | 4656.10 | +62.60 | +1.36% |
| R1 | 4624.80 | +31.30 | +0.68% |
| PIVOT | 4587.60 | -5.90 | -0.13% |
| CURRENT | 4593.50 | — | — |
| S1 | 4556.30 | -37.20 | -0.81% |
| S2 | 4519.10 | -74.40 | -1.62% |
| S3 | 4487.80 | -105.70 | -2.30% |
| S4 | 4419.30 | -174.20 | -3.79% |
TORNTPHARM is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹4584.1–₹4618.9
Trading Inside opening range
TORRENT PHARMACEUTICALS L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for TORRENT PHARMACEUTICALS L — consolidated or standalone — with margins, YoY growth and key ratios inline.
TORRENT PHARMACEUTICALS L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.74 L Cr. and reported EPS of ₹16.72.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 13,980 | 13,980 ▲ 0.0% |
| Sales Growth YoY %Derived | 21.40% | 21.40% |
| Other Income | -94 | -94 ▲ 0.0% |
| Total Income | 13,886 | 13,886 ▲ 0.0% |
| 3,388 | 3,388 ▲ 0.0% | |
| Gross ProfitDerived | 10,592 | 10,592 ▲ 0.0% |
| Gross Margin %Derived | 75.77% | 75.77% |
| 6,033 | 6,033 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 4,559 | 4,559 ▲ 0.0% |
| OPM %Derived | 32.61% | 32.61% |
| 1,415 | 1,415 ▲ 0.0% | |
| Profit Before Tax (PBT) | 2,872 | 2,872 ▲ 0.0% |
| 734 | 734 ▲ 0.0% | |
| Effective Tax %Derived | 25.56% | 25.56% |
| Total Profit for Period | 2,138 | 2,138 ▲ 0.0% |
| Less: Non-controlling Interests | -25 | -25 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 2,163 | 2,163 ▲ 0.0% |
| Net Profit Margin %Derived | 15.47% | 15.47% |
| PAT Growth YoY %Derived | 13.19% | 13.19% |
| Earnings Per Share (EPS ₹) | 63.91 | 63.91 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 34 | 34 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -180 | -180 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 11,014 | 11,014 ▲ 0.0% |
| Material Cost % of RevenueDerived | 12.58% | 12.58% |
| Employee Cost % of RevenueDerived | 19.11% | 19.11% |
| Other Cost % of RevenueDerived | 24.05% | 24.05% |
| Interest Coverage (x)Derived | 8.94x | 8.94x |
| Period | Mar 2018 | Jul 2018 | Mar 2019 | Jun 2019 | Mar 2020 | Jun 2020 | Mar 2021 | May 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 6,002 | 6,002 ▲ 0.0% | 7,673 ▲ 27.8% | 7,673 ▲ 0.0% | 7,939 ▲ 3.5% | 7,939 ▲ 0.0% | 8,005 ▲ 0.8% | 8,005 ▲ 0.0% | 8,508 ▲ 6.3% | 8,508 ▲ 0.0% | 9,620 ▲ 13.1% | 9,620 ▲ 0.0% | 10,728 ▲ 11.5% | 10,728 ▲ 0.0% | 11,516 ▲ 7.3% | 11,516 ▲ 0.0% | 13,980 ▲ 21.4% | 13,980 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 27.84% | — | 3.47% | 3.47% | 0.83% | — | 6.28% | 6.28% | 13.07% | 13.07% | 11.52% | 11.52% | 7.35% | 7.35% | 21.40% | 21.40% | |
| Other Income | 299 | 299 ▲ 0.0% | 57 ▼ 80.9% | 57 ▲ 0.0% | 122 ▲ 114.0% | 122 ▲ 0.0% | 57 ▼ 53.3% | 57 ▲ 0.0% | 197 ▲ 245.6% | 197 ▲ 0.0% | 45 ▼ 77.2% | 45 ▲ 0.0% | 58 ▲ 28.9% | 58 ▲ 0.0% | 23 ▼ 60.3% | 23 ▲ 0.0% | -94 ▼ 508.7% | -94 ▲ 0.0% | |
| Total Income | 6,301 | 6,301 ▲ 0.0% | 7,730 ▲ 22.7% | 7,730 ▲ 0.0% | 8,061 ▲ 4.3% | 8,061 ▲ 0.0% | 8,062 ▲ 0.0% | 8,062 ▲ 0.0% | 8,705 ▲ 8.0% | 8,705 ▲ 0.0% | 9,665 ▲ 11.0% | 9,665 ▲ 0.0% | 10,786 ▲ 11.6% | 10,786 ▲ 0.0% | 11,539 ▲ 7.0% | 11,539 ▲ 0.0% | 13,886 ▲ 20.3% | 13,886 ▲ 0.0% | |
1,674 | 1,674 ▲ 0.0% | 2,219 ▲ 32.6% | 2,219 ▲ 0.0% | 2,167 ▼ 2.3% | 2,167 ▲ 0.0% | 2,147 ▼ 0.9% | 2,147 ▲ 0.0% | 2,443 ▲ 13.8% | 2,443 ▲ 0.0% | 2,735 ▲ 12.0% | 2,735 ▲ 0.0% | 2,686 ▼ 1.8% | 2,686 ▲ 0.0% | 2,776 ▲ 3.4% | 2,776 ▲ 0.0% | 3,388 ▲ 22.0% | 3,388 ▲ 0.0% | ||
| Gross ProfitDerived | 4,328 | 4,328 ▲ 0.0% | 5,454 ▲ 26.0% | 5,454 ▲ 0.0% | 5,772 ▲ 5.8% | 5,772 ▲ 0.0% | 5,858 ▲ 1.5% | 5,858 ▲ 0.0% | 6,065 ▲ 3.5% | 6,065 ▲ 0.0% | 6,885 ▲ 13.5% | 6,885 ▲ 0.0% | 8,042 ▲ 16.8% | 8,042 ▲ 0.0% | 8,740 ▲ 8.7% | 8,740 ▲ 0.0% | 10,592 ▲ 21.2% | 10,592 ▲ 0.0% | |
| Gross Margin %Derived | 72.11% | 72.11% | 71.08% | 71.08% | 72.70% | 72.70% | 73.18% | 73.18% | 71.29% | 71.29% | 71.57% | 71.57% | 74.96% | 74.96% | 75.89% | 75.89% | 75.77% | 75.77% | |
2,979 | 2,979 ▲ 0.0% | 3,470 ▲ 16.5% | 3,470 ▲ 0.0% | 3,602 ▲ 3.8% | 3,602 ▲ 0.0% | 3,373 ▼ 6.4% | 3,373 ▲ 0.0% | 3,634 ▲ 7.7% | 3,634 ▲ 0.0% | 4,043 ▲ 11.3% | 4,043 ▲ 0.0% | 4,674 ▲ 15.6% | 4,674 ▲ 0.0% | 5,019 ▲ 7.4% | 5,019 ▲ 0.0% | 6,033 ▲ 20.2% | 6,033 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 1,349 | 1,349 ▲ 0.0% | 1,984 ▲ 47.1% | 1,984 ▲ 0.0% | 2,170 ▲ 9.4% | 2,170 ▲ 0.0% | 2,485 ▲ 14.5% | 2,485 ▲ 0.0% | 2,431 ▼ 2.2% | 2,431 ▲ 0.0% | 2,842 ▲ 16.9% | 2,842 ▲ 0.0% | 3,368 ▲ 18.5% | 3,368 ▲ 0.0% | 3,721 ▲ 10.5% | 3,721 ▲ 0.0% | 4,559 ▲ 22.5% | 4,559 ▲ 0.0% | |
| OPM %Derived | 22.48% | 22.48% | 25.86% | 25.86% | 27.33% | 27.33% | 31.04% | 31.04% | 28.57% | 28.57% | 29.54% | 29.54% | 31.39% | 31.39% | 32.31% | 32.31% | 32.61% | 32.61% | |
717 | 717 ▲ 0.0% | 765 ▲ 6.7% | 765 ▲ 0.0% | 1,105 ▲ 44.4% | 1,105 ▲ 0.0% | 1,016 ▼ 8.1% | 1,016 ▲ 0.0% | 432 ▼ 57.5% | 432 ▲ 0.0% | 1,040 ▲ 140.7% | 1,040 ▲ 0.0% | 1,250 ▲ 20.2% | 1,250 ▲ 0.0% | 1,023 ▼ 18.2% | 1,023 ▲ 0.0% | 1,415 ▲ 38.3% | 1,415 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 931 | 931 ▲ 0.0% | 562 ▼ 39.6% | 562 ▲ 0.0% | 1,187 ▲ 111.2% | 1,187 ▲ 0.0% | 1,526 ▲ 28.6% | 1,526 ▲ 0.0% | 1,226 ▼ 19.7% | 1,226 ▲ 0.0% | 1,847 ▲ 50.7% | 1,847 ▲ 0.0% | 2,352 ▲ 27.3% | 2,352 ▲ 0.0% | 2,673 ▲ 13.6% | 2,673 ▲ 0.0% | 2,872 ▲ 7.4% | 2,872 ▲ 0.0% | |
253 | 253 ▲ 0.0% | 126 ▼ 50.2% | 126 ▲ 0.0% | 162 ▲ 28.6% | 162 ▲ 0.0% | 274 ▲ 69.1% | 274 ▲ 0.0% | 449 ▲ 63.9% | 449 ▲ 0.0% | 602 ▲ 34.1% | 602 ▲ 0.0% | 696 ▲ 15.6% | 696 ▲ 0.0% | 762 ▲ 9.5% | 762 ▲ 0.0% | 734 ▼ 3.7% | 734 ▲ 0.0% | ||
| Effective Tax %Derived | 27.18% | 27.18% | 22.42% | 22.42% | 13.65% | 13.65% | 17.96% | 17.96% | 36.62% | 36.62% | 32.59% | 32.59% | 29.59% | 29.59% | 28.51% | 28.51% | 25.56% | 25.56% | |
| Total Profit for Period | 678 | 678 ▲ 0.0% | 436 ▼ 35.7% | 436 ▲ 0.0% | 1,025 ▲ 135.1% | 1,025 ▲ 0.0% | 1,252 ▲ 22.1% | 1,252 ▲ 0.0% | 777 ▼ 37.9% | 777 ▲ 0.0% | 1,245 ▲ 60.2% | 1,245 ▲ 0.0% | 1,656 ▲ 33.0% | 1,656 ▲ 0.0% | 1,911 ▲ 15.4% | 1,911 ▲ 0.0% | 2,138 ▲ 11.9% | 2,138 ▲ 0.0% | |
| Less: Non-controlling Interests | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -25 | -25 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 678 | 678 ▲ 0.0% | 436 ▼ 35.7% | 436 ▲ 0.0% | 1,025 ▲ 135.1% | 1,025 ▲ 0.0% | 1,252 ▲ 22.1% | 1,252 ▲ 0.0% | 777 ▼ 37.9% | 777 ▲ 0.0% | 1,245 ▲ 60.2% | 1,245 ▲ 0.0% | 1,656 ▲ 33.0% | 1,656 ▲ 0.0% | 1,911 ▲ 15.4% | 1,911 ▲ 0.0% | 2,163 ▲ 13.2% | 2,163 ▲ 0.0% | |
| Net Profit Margin %Derived | 11.30% | 11.30% | 5.68% | 5.68% | 12.91% | 12.91% | 15.64% | 15.64% | 9.13% | 9.13% | 12.94% | 12.94% | 15.44% | 15.44% | 16.59% | 16.59% | 15.47% | 15.47% | |
| PAT Growth YoY %Derived | — | — | -35.69% | — | 135.09% | 135.09% | 22.15% | — | -37.94% | -37.94% | 60.23% | 60.23% | 33.01% | 33.01% | 15.40% | 15.40% | 13.19% | 13.19% | |
| Earnings Per Share (EPS ₹) | 20.03 | 20.03 ▲ 0.0% | 12.88 ▼ 35.7% | 12.88 ▲ 0.0% | 30.29 ▲ 135.2% | 30.29 ▲ 0.0% | 36.99 ▲ 22.1% | 36.99 ▲ 0.0% | 22.96 ▼ 37.9% | 22.96 ▲ 0.0% | 36.79 ▲ 60.2% | 36.79 ▲ 0.0% | 48.93 ▲ 33.0% | 48.93 ▲ 0.0% | 56.46 ▲ 15.4% | 56.46 ▲ 0.0% | 63.91 ▲ 13.2% | 63.91 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 34 | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | 34 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -141 | -141 ▲ 0.0% | 33 ▲ 123.4% | 33 ▲ 0.0% | -192 ▼ 681.8% | -192 ▲ 0.0% | 100 ▲ 152.1% | 100 ▲ 0.0% | 12 ▼ 88.0% | 12 ▲ 0.0% | -137 ▼ 1241.7% | -137 ▲ 0.0% | 17 ▲ 112.4% | 17 ▲ 0.0% | -93 ▼ 647.1% | -93 ▲ 0.0% | -180 ▼ 93.5% | -180 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 5,370 | 5,370 ▲ 0.0% | 7,168 ▲ 33.5% | 7,168 ▲ 0.0% | 6,874 ▼ 4.1% | 6,874 ▲ 0.0% | 6,536 ▼ 4.9% | 6,536 ▲ 0.0% | 7,479 ▲ 14.4% | 7,479 ▲ 0.0% | 7,818 ▲ 4.5% | 7,818 ▲ 0.0% | 8,434 ▲ 7.9% | 8,434 ▲ 0.0% | 8,866 ▲ 5.1% | 8,866 ▲ 0.0% | 11,014 ▲ 24.2% | 11,014 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 17.31% | 17.31% | 16.81% | 16.81% | 17.34% | 17.34% | 17.75% | 17.75% | 18.08% | 18.08% | 15.38% | 15.38% | 15.45% | 15.45% | 13.20% | 13.20% | 12.58% | 12.58% | |
| Employee Cost % of RevenueDerived | 18.91% | 18.91% | 18.30% | 18.30% | 18.00% | 18.00% | 17.99% | 17.99% | 17.94% | 17.94% | 17.44% | 17.44% | 18.49% | 18.49% | 19.13% | 19.13% | 19.11% | 19.11% | |
| Other Cost % of RevenueDerived | 30.72% | 30.72% | 26.93% | 26.93% | 27.37% | 27.37% | 24.15% | 24.15% | 24.78% | 24.78% | 24.58% | 24.58% | 25.07% | 25.07% | 24.45% | 24.45% | 24.05% | 24.05% | |
| Interest Coverage (x)Derived | 3.05x | 3.05x | 2.71x | 2.71x | 3.36x | 3.36x | 5.10x | 5.10x | 6.94x | 6.94x | 6.41x | 6.41x | 7.23x | 7.23x | 11.61x | 11.61x | 8.94x | 8.94x |
TORRENT PHARMACEUTICALS L segment analysis : revenue and profit mix.
Disclosed business segments at TORRENT PHARMACEUTICALS L with their share of revenue and profit, switchable between consolidated and standalone reporting.
TORRENT PHARMACEUTICALS L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for TORRENT PHARMACEUTICALS L.
Our AI distills the core fundamental drivers supporting TORRENT PHARMACEUTICALS L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 93 (~2.3× the sector multiple of 39.9) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.34. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
TORRENT PHARMACEUTICALS L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — TORRENT PHARMACEUTICALS L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
TORRENT PHARMACEUTICALS L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for TORRENT PHARMACEUTICALS L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
TORRENT PHARMACEUTICALS L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for TORRENT PHARMACEUTICALS L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in TORRENT PHARMACEUTICALS L stood at 64.3% of traded volume, against a 20-day average of 61.7%.
TORRENT PHARMACEUTICALS L announcements: results, concalls, ratings, M&A.
Filings TORRENT PHARMACEUTICALS L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
TORRENT PHARMACEUTICALS L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 179 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Credit Rating
Torrent Pharmaceuticals Limited has informed the Exchange about Credit Rating
Acquisition
Torrent Pharmaceuticals Limited has informed the Exchange about Acquisition - Disclosure pursuant to Regulation 30 read with Schedule III of SEBI…
Trading Window
Torrent Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Analysts/Institutional Investor Meet/Con. Call Updates
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Credit Rating
Credit Rating
Credit Rating
Credit Rating
Credit Rating- New
Credit Rating
TORRENT PHARMACEUTICALS L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue TORRENT PHARMACEUTICALS L has declared, sequenced by announce and record date.
TORRENT PHARMACEUTICALS L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About TORRENT PHARMACEUTICALS L: business, sector, key facts.
What TORRENT PHARMACEUTICALS L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
TORRENT PHARMACEUTICALS L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: TORNTPHARM, BSE: 500420.
Torrent Pharmaceuticals Limited is a global pharmaceutical company headquartered in Ahmedabad, India, with a significant presence in several key international markets including the United States, Brazil, and Germany. The company's core business focuses on the research, development, manufacturing, and marketing of generic pharmaceutical formulations. This means they produce and sell less expensive versions of brand-name drugs once their patents have expired, making them accessible to a wider patient population.
Their product portfolio spans a broad range of therapeutic areas, addressing diverse health needs. Key areas of focus include cardiovascular health (treating heart conditions), central nervous system disorders (affecting the brain and nerves), gastrointestinal issues (relating to the digestive system), and women's healthcare. Beyond these core areas, they also offer products in dermatology (skin conditions), diabetology (diabetes management), pain management, gynecology, oncology (cancer treatment), and anti-infective medications (fighting infections). They also produce and distribute vitamins, minerals, and nutritional supplements.
In addition to its own branded products, Torrent Pharmaceuticals also provides contract manufacturing services. This means the company manufactures pharmaceuticals for other companies, leveraging its established manufacturing capabilities and expertise to provide a service to the broader pharmaceutical industry. This diversification contributes to the company's overall revenue streams and operational stability.
With a history dating back to 1959, Torrent Pharmaceuticals, formerly known as Trinity Laboratories, has established itself as a prominent player in the global generic pharmaceutical market. Its operations extend across multiple continents, demonstrating a successful international expansion strategy. The company is a subsidiary of Torrent Investments Private Limited, reflecting its position within a larger corporate structure.
Go deeper on TORRENT PHARMACEUTICALS L
- TORRENT PHARMACEUTICALS L resultsQuarter-by-quarter revenue, profit, EPS and margins for TORRENT PHARMACEUTICALS L.
- TORRENT PHARMACEUTICALS L dividendEvery dividend TORRENT PHARMACEUTICALS L has declared, with ex-dates and yield.
- TORRENT PHARMACEUTICALS L shareholdingPromoter, FII and DII holding in TORRENT PHARMACEUTICALS L, quarter by quarter.
- TORRENT PHARMACEUTICALS L financialsTORRENT PHARMACEUTICALS L profit & loss, balance sheet and cash flow by year.
- TORRENT PHARMACEUTICALS L technical analysisPivots, CPR and live indicator readings for TORRENT PHARMACEUTICALS L.
- TORRENT PHARMACEUTICALS L corporate actionsBonus issues, splits, rights and buybacks declared by TORRENT PHARMACEUTICALS L.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about TORRENT PHARMACEUTICALS L (TORNTPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of TORRENT PHARMACEUTICALS L (TORNTPHARM)?
The current share price of TORRENT PHARMACEUTICALS L (TORNTPHARM) is ₹4,593.50. Today, the stock has gained by ₹9.40 (0.21%), trading in a range of ₹4,550.40 to ₹4,618.90. The stock opened at ₹4,584.10 with a trading volume of 68,861 shares.
02Is TORRENT PHARMACEUTICALS L stock a good investment for long-term?
TORRENT PHARMACEUTICALS L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1.74 L Cr., P/E ratio of 71.32, ROE of 12.16%, and ROCE of 7.75%. The dividend yield stands at 0.83%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of TORRENT PHARMACEUTICALS L stock?
The 52-week high price of TORRENT PHARMACEUTICALS L (TORNTPHARM) is ₹5,250.00, while the 52-week low is ₹3,505.50. Currently trading at ₹4,593.50, the stock is 31.04% above its 52-week low and 12.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy TORRENT PHARMACEUTICALS L stock at the current price?
Whether to buy TORRENT PHARMACEUTICALS L stock at ₹4,593.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 71.32 and P/B ratio of 18.54. Today's performance shows a gain of 0.21%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of TORRENT PHARMACEUTICALS L and when is the next dividend?
TORRENT PHARMACEUTICALS L offers a dividend yield of 0.83%, which means for every ₹100 invested at the current price of ₹4,593.50, you can expect to receive approximately ₹0.83 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of TORRENT PHARMACEUTICALS L?
TORRENT PHARMACEUTICALS L's key financial metrics include: P/E Ratio: 71.32, P/B Ratio: 18.54, ROE: 12.16%, ROCE: 7.75%, Dividend Yield: 0.83%, EPS: ₹16.72, Book Value: ₹519.58, and Debt-to-Equity: 0.84. The company's market cap stands at ₹1.74 L Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is TORRENT PHARMACEUTICALS L stock performing today in the market?
TORRENT PHARMACEUTICALS L stock opened at ₹4,584.10 and is currently trading at ₹4,593.50, showing a gain of ₹9.40 (0.21%). The intraday high is ₹4,618.90 and low is ₹4,550.40. The trading volume stands at 68,861 shares, indicating moderate market participation today.
08What is the P/E ratio of TORRENT PHARMACEUTICALS L and what does it indicate?
TORRENT PHARMACEUTICALS L has a Price-to-Earnings (P/E) ratio of 71.32, which means investors are willing to pay 71.32 for every ₹1 of earnings. With an EPS of ₹16.72, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about TORRENT PHARMACEUTICALS L (TORNTPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.